dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
Published 7 years ago • 374 plays • Length 1:18Download video MP4
Download video MP3
Similar videos
-
1:06
dr. neal on immunotherapy combinations in lung cancer
-
1:20
dr. neal on exciting advancements in the field of lung cancer
-
1:04
dr. neal on ongoing trials of immunotherapy for lung cancer
-
1:55
dr. hirsch on value of pd-l1 testing in patients with lung cancer
-
1:56
dr. levy on impact of nivolumab, pembrolizumab approvals in nsclc
-
8:05
how does pd-l1 score affect treatment options? - lung cancer onctalk 2022
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
6:56
all you need to know about pd-l1 by immunohistochemistry
-
1:42
dr. desai on immunotherapy in patients with nsclc and low pd-l1 expression
-
5:44
reliability of pd-l1 testing in nsclc
-
0:56
pembrolizumab and the significance of pd-l1 for lung cancer
-
2:03
antibiotics impact outcomes with pembrolizumab in nsclc patients
-
10:20
pd-l1 testing in advanced lung cancer
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
1:22
updated outcomes of keynote-010 of pembrolizumab for nsclc
-
3:42
first line pembrolizumab in pd-l1 tps 90% nsclc
-
4:41
pd-l1 testing for nsclc
-
0:59
dr. johung on prognosis of patients with alk-rearranged nsclc and brain metastases
-
4:36
efficacy and safety of checkpoint inhibitors in lung cancer
-
2:30
dr. lopes on the keynote-042 results of frontline pembrolizumab in nsclc
-
1:48
dr. brahmer discusses frontline single-agent pembrolizumab in lung cancer
-
18:58
pd-l1 testing by immunohistochemistry